当前位置:首页 - 行情中心 - 名臣健康(002919) - 财务分析 - 利润表

名臣健康

(002919)

  

流通市值:47.38亿  总市值:47.76亿
流通股本:2.64亿   总股本:2.67亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入711,668,800.05361,419,226.731,380,254,020.51984,704,973.19
  营业收入711,668,800.05361,419,226.731,380,254,020.51984,704,973.19
二、营业总成本673,425,511.37340,518,894.231,279,892,804.36852,236,672.12
  营业成本329,242,376.05157,926,236.96655,621,816.29377,292,545.81
  税金及附加2,042,234.89724,315.215,358,600.753,636,692.94
  销售费用267,349,883.84146,167,531.44443,621,398.89346,351,879.32
  管理费用46,851,976.3822,038,110.4106,043,406.676,435,382.09
  研发费用27,805,680.8513,676,400.0269,410,518.0248,895,920.66
  财务费用133,359.36-13,699.8-162,936.19-375,748.7
  其中:利息费用466,641.42232,511.071,584,358.091,162,930.05
  其中:利息收入343,491.46198,709.941,051,535.16842,153.63
三、其他经营收益
  加:公允价值变动收益309,669.4139,580.85376,726.21145,223.49
  加:投资收益147,972.1379,033.26147,045.64146,789.23
  资产处置收益233,240.96-182,061.134,381,300.683,782,754.23
  资产减值损失(新)-267,678.53--24,415,616.12-5,226,222.62
  信用减值损失(新)-1,809,177.9-6,417,941.31-49,924,933.59-22,091,174.49
  其他收益341,247.68255,364.28406,211.75248,650.07
四、营业利润37,198,562.4214,774,308.4531,331,950.72109,474,320.98
  加:营业外收入37,718.355,009.82866,747.34126,226.41
  减:营业外支出578,529.151,560.844,719,881.012,785,152.55
五、利润总额36,657,751.6214,777,757.4327,478,817.05106,815,394.84
  减:所得税费用-4,399,777.762,030,124.67-19,238,335.8410,025,078.73
六、净利润41,057,529.3812,747,632.7646,717,152.8996,790,316.11
(一)按经营持续性分类
  持续经营净利润41,057,529.3812,747,632.7646,717,152.8996,790,316.11
(二)按所有权归属分类
  归属于母公司股东的净利润41,062,613.1212,713,011.4946,719,608.8296,778,082.38
  少数股东损益-5,083.7434,621.27-2,455.9312,233.73
  扣除非经常损益后的净利润40,763,947.6212,608,385.945,983,843.8595,926,447.88
七、每股收益
  (一)基本每股收益0.150.050.180.36
  (二)稀释每股收益0.150.050.180.36
九、综合收益总额41,057,529.3812,747,632.7646,717,152.8996,790,316.11
  归属于母公司股东的综合收益总额41,062,613.1212,713,011.4946,719,608.8296,778,082.38
  归属于少数股东的综合收益总额-5,083.7434,621.27-2,455.9312,233.73
公告日期2025-08-292025-04-292025-04-292024-10-30
审计意见(境内)标准无保留意见
TOP↑